{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:51:21Z","timestamp":1781769081641,"version":"3.54.5"},"reference-count":44,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:p>OBJECTIVES. High-dose recombinant erythropoietin is neuroprotective in animal models of neonatal brain injury. Extremely low birth weight infants are at high risk for brain injury and neurodevelopmental problems and might benefit from recombinant erythropoietin. We designed a phase I\/II trial to test the safety and determine the pharmacokinetics of high-dose recombinant erythropoietin in extremely low birth weight infants.<\/jats:p>\n               <jats:p>METHODS. In a prospective, dose-escalation, open-label trial, we compared 30 infants who were treated with high-dose recombinant erythropoietin with 30 concurrent control subjects. Eligible infants were &amp;lt;24 hours old, \u22641000 g birth weight, and \u226428 weeks of gestation and had an umbilical artery catheter in place. Each infant received 3 intravenous doses of 500, 1000, or 2500 U\/kg at 24-hour intervals beginning on day 1 of age. Blood samples were collected at scheduled intervals to determine recombinant erythropoietin pharmacokinetics. Safety parameters were also evaluated. In the concurrent control group, only clinical data were collected.<\/jats:p>\n               <jats:p>RESULTS. Mean erythropoietin concentrations 30 minutes after recombinant erythropoietin infusion were 5973 \u00b1 266, 12291 \u00b1 403, and 34197 \u00b1 1641 mU\/mL after 500, 1000, or 2500 U\/kg, respectively. High-dose recombinant erythropoietin followed nonlinear pharmacokinetics as a result of decreasing clearance from the lowest dosage (17.3 mL\/hour per kg for 500 U\/kg) to the highest dosage (8.2 mL\/hour per kg for 2500 U\/kg). Steady state was achieved within 24 to 48 hours. Both 1000 and 2500 U\/kg recombinant erythropoietin produced peak serum erythropoietin concentrations that were comparable to neuroprotective concentrations that previously were seen in experimental animals. No excess adverse events occurred in the recombinant erythropoietin\u2013treated infants compared with control infants.<\/jats:p>\n               <jats:p>CONCLUSIONS. Early high-dose recombinant erythropoietin is well tolerated by extremely low birth weight infants, causing no excess morbidity or mortality. Recombinant erythropoietin dosages of 1000 and 2500 U\/kg achieved neuroprotective serum levels.<\/jats:p>","DOI":"10.1542\/peds.2007-2711","type":"journal-article","created":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T13:38:30Z","timestamp":1217597910000},"page":"383-391","source":"Crossref","is-referenced-by-count":161,"title":["A Phase I\/II Trial of High-Dose Erythropoietin in Extremely Low Birth Weight Infants: Pharmacokinetics and Safety"],"prefix":"10.1542","volume":"122","author":[{"given":"Sandra E.","family":"Juul","sequence":"first","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"McPherson","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Pharmacy and Laboratory Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Ledbetter","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Gleason","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis E.","family":"Mayock","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,8,1]]},"reference":[{"key":"2021120906001048200_R1","doi-asserted-by":"crossref","unstructured":"Meadow W, Lee G, Lin K, Lantos J. Changes in mortality for extremely low birth weight infants in the 1990s: implications for treatment decisions and resource use. Pediatrics.\u20082004;113(5):1223\u20131229","DOI":"10.1542\/peds.113.5.1223"},{"key":"2021120906001048200_R2","doi-asserted-by":"crossref","unstructured":"Hack M, Youngstrom EA, Cartar L, et al. Behavioral outcomes and evidence of psychopathology among very low birth weight infants at age 20 years. Pediatrics.\u20082004;114(4):932\u2013940","DOI":"10.1542\/peds.2003-1017-L"},{"key":"2021120906001048200_R3","doi-asserted-by":"crossref","unstructured":"Litt J, Taylor HG, Klein N, Hack M. Learning disabilities in children with very low birthweight: prevalence, neuropsychological correlates, and educational interventions. J Learn Disabil.\u20082005;38(2):130\u2013141","DOI":"10.1177\/00222194050380020301"},{"key":"2021120906001048200_R4","doi-asserted-by":"crossref","unstructured":"Wilson-Costello D, Friedman H, Minich N, Fanaroff AA, Hack M. Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics.\u20082005;115(4):997\u20131003","DOI":"10.1542\/peds.2004-0221"},{"key":"2021120906001048200_R5","doi-asserted-by":"crossref","unstructured":"Moore M, Gerry Taylor H, Klein N, Minich N, Hack M. Longitudinal changes in family outcomes of very low birth weight. J Pediatr Psychol.\u20082006;31(10):1024\u20131035","DOI":"10.1093\/jpepsy\/jsj075"},{"key":"2021120906001048200_R6","doi-asserted-by":"crossref","unstructured":"Vohr BR, Wright LL, Dusick AM, et al. Center differences and outcomes of extremely low birth weight infants. Pediatrics.\u20082004;113(4):781\u2013789","DOI":"10.1542\/peds.113.4.781"},{"key":"2021120906001048200_R7","doi-asserted-by":"crossref","unstructured":"Kluckow M, Evans N. Low superior vena cava flow and intraventricular haemorrhage in preterm infants. Arch Dis Child Fetal Neonatal Ed.\u20082000;82(3):F188\u2013F194","DOI":"10.1136\/fn.82.3.F188"},{"key":"2021120906001048200_R8","doi-asserted-by":"crossref","unstructured":"Demers EJ, McPherson RJ, Juul SE. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia. Pediatr Res.\u20082005;58(2):297\u2013301","DOI":"10.1203\/01.PDR.0000169971.64558.5A"},{"key":"2021120906001048200_R9","doi-asserted-by":"crossref","unstructured":"Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res.\u20082007;61(4):451\u2013455","DOI":"10.1203\/pdr.0b013e3180332cec"},{"key":"2021120906001048200_R10","doi-asserted-by":"crossref","unstructured":"Dzietko M, Felderhoff-Mueser U, Sifringer M, et al. Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol Dis.\u20082004;15(2):177\u2013187","DOI":"10.1016\/j.nbd.2003.10.006"},{"key":"2021120906001048200_R11","doi-asserted-by":"crossref","unstructured":"Keller M, Yang J, Griesmaier E, et al. Erythropoietin is neuroprotective against NMDA-receptor-mediated excitotoxic brain injury in newborn mice. Neurobiol Dis.\u20082006;24(2):357\u2013366","DOI":"10.1016\/j.nbd.2006.07.007"},{"key":"2021120906001048200_R12","doi-asserted-by":"crossref","unstructured":"Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res.\u20082007;61(6):671\u2013675","DOI":"10.1203\/pdr.0b013e31805341dc"},{"key":"2021120906001048200_R13","unstructured":"Amgen. Epogen (epoietin alfa) for injection. 2005. Available at: www.fda.gov\/medwatch\/safety\/2008\/epo_DHCP_03102008.pdf. Accessed June 17, 2008"},{"key":"2021120906001048200_R14","doi-asserted-by":"crossref","unstructured":"Ohls RK. The use of erythropoietin in neonates. Clin Perinatol.\u20082000;27(3):681\u2013696","DOI":"10.1016\/S0095-5108(05)70045-2"},{"key":"2021120906001048200_R15","doi-asserted-by":"crossref","unstructured":"Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate.\u20082004;85(2):138\u2013144","DOI":"10.1159\/000074970"},{"key":"2021120906001048200_R16","doi-asserted-by":"crossref","unstructured":"Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med.\u20082002;8(8):495\u2013505","DOI":"10.1007\/BF03402029"},{"key":"2021120906001048200_R17","doi-asserted-by":"crossref","unstructured":"Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry.\u20082007;12(2):206\u2013220","DOI":"10.1038\/sj.mp.4001907"},{"key":"2021120906001048200_R18","doi-asserted-by":"crossref","unstructured":"Pollak A, Hayde M, Hayn M, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. Pediatrics.\u20082001;107(1):78\u201385","DOI":"10.1542\/peds.107.1.78"},{"key":"2021120906001048200_R19","doi-asserted-by":"crossref","unstructured":"Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and\/or low birth weight infants. Cochrane Database Syst Rev.\u20082006;(3):CD004863","DOI":"10.1002\/14651858.CD004863.pub2"},{"key":"2021120906001048200_R20","doi-asserted-by":"crossref","unstructured":"Juul SE, Zerzan JC, Strandjord TP, Woodrum DE. Zinc protoporphyrin\/heme as an indicator of iron status in NICU patients. J Pediatr.\u20082003;142(3):273\u2013278","DOI":"10.1067\/mpd.2003.101"},{"key":"2021120906001048200_R21","doi-asserted-by":"crossref","unstructured":"Roberts IIL, Morrow J. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med.\u20082000;28(4):505\u2013513","DOI":"10.1016\/S0891-5849(99)00264-6"},{"key":"2021120906001048200_R22","doi-asserted-by":"crossref","unstructured":"Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond).\u20081993;84(4):407\u2013412","DOI":"10.1042\/cs0840407"},{"key":"2021120906001048200_R23","doi-asserted-by":"crossref","unstructured":"Buonocore G, Perrone S, Longini M, et al. Non protein bound iron as early predictive marker of neonatal brain damage. Brain.\u20082003;126(Pt 5):1224\u20131230","DOI":"10.1093\/brain\/awg116"},{"key":"2021120906001048200_R24","doi-asserted-by":"crossref","unstructured":"Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider R. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem.\u20081999;273(2):212\u2013220","DOI":"10.1006\/abio.1999.4216"},{"key":"2021120906001048200_R25","doi-asserted-by":"crossref","unstructured":"Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol.\u20081996;80(1):140\u2013148","DOI":"10.1152\/jappl.1996.80.1.140"},{"key":"2021120906001048200_R26","doi-asserted-by":"crossref","unstructured":"Widness JA, Schmidt RL, Hohl RJ, et al. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther.\u20082007;81(6):873\u2013879","DOI":"10.1038\/sj.clpt.6100165"},{"key":"2021120906001048200_R27","doi-asserted-by":"crossref","unstructured":"Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci.\u20081979;68(8):1071\u20131074","DOI":"10.1002\/jps.2600680845"},{"key":"2021120906001048200_R28","doi-asserted-by":"crossref","unstructured":"Perrier D, Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci.\u20081982;71(3):372\u2013373","DOI":"10.1002\/jps.2600710332"},{"key":"2021120906001048200_R29","doi-asserted-by":"crossref","unstructured":"Brown MS, Jones MA, Ohls RK, Christensen RD. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J Pediatr.\u20081993;122(4):655\u2013657","DOI":"10.1016\/S0022-3476(05)83559-0"},{"key":"2021120906001048200_R30","doi-asserted-by":"crossref","unstructured":"Bozzini CE. Influence of the erythroid activity of the bone marrow on the plasma disappearance of injected erythropoietin in dogs. Nature.\u20081966;209(5028):1140\u20131141","DOI":"10.1038\/2091140b0"},{"key":"2021120906001048200_R31","unstructured":"Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med.\u20081987;109(4):429\u2013433"},{"key":"2021120906001048200_R32","doi-asserted-by":"crossref","unstructured":"Emmanouel DS, Goldwasser E, Katz AI. Metabolism of pure human erythropoietin in the rat. Am J Physiol.\u20081984;247(1 pt 2):F168\u2013F176","DOI":"10.1152\/ajprenal.1984.247.1.F168"},{"key":"2021120906001048200_R33","doi-asserted-by":"crossref","unstructured":"Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet.\u20081991;20(2):99\u2013113","DOI":"10.2165\/00003088-199120020-00002"},{"key":"2021120906001048200_R34","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Caro J. Erythropoietin: physiologic basis for clinical applications. Vox Sang.\u20081993;65(3):169\u2013179","DOI":"10.1111\/j.1423-0410.1993.tb02143.x"},{"key":"2021120906001048200_R35","doi-asserted-by":"crossref","unstructured":"Kindler J, Eckardt KU, Ehmer B, Jandeleit K, Kurtz A, Schreiber A, Scigalla P, Sieberth HG. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant.\u20081989;4(5):345\u2013349","DOI":"10.1093\/oxfordjournals.ndt.a091888"},{"key":"2021120906001048200_R36","unstructured":"Widness JA, Veng-Pedersen P, Schmidt RL, Lowe LS, Kisthard JA, Peters C. In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther.\u20081996;279(3):1205\u20131210"},{"key":"2021120906001048200_R37","doi-asserted-by":"crossref","unstructured":"Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood.\u20081989;73(1):90\u201399","DOI":"10.1182\/blood.V73.1.90.bloodjournal73190"},{"key":"2021120906001048200_R38","doi-asserted-by":"crossref","unstructured":"Kato M, Kato Y, Sugiyama Y. Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. Am J Physiol.\u20081999;276(5 pt 1):E887\u2013E895","DOI":"10.1152\/ajpendo.1999.276.5.E887"},{"key":"2021120906001048200_R39","doi-asserted-by":"crossref","unstructured":"Sawyer ST, Krantz SB, Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem.\u20081987;262(12):5554\u20135562","DOI":"10.1016\/S0021-9258(18)45608-6"},{"key":"2021120906001048200_R40","doi-asserted-by":"crossref","unstructured":"Mufson RA, Gesner TG. Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood.\u20081987;69(5):1485\u20131490","DOI":"10.1182\/blood.V69.5.1485.bloodjournal6951485"},{"key":"2021120906001048200_R41","doi-asserted-by":"crossref","unstructured":"Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev.\u20081998;52(3):235\u2013249","DOI":"10.1016\/S0378-3782(98)00030-9"},{"key":"2021120906001048200_R42","doi-asserted-by":"crossref","unstructured":"Grasso G, Buemi M, Alafaci C, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA.\u20082002;99(8):5627\u20135631","DOI":"10.1073\/pnas.082097299"},{"key":"2021120906001048200_R43","doi-asserted-by":"crossref","unstructured":"Juul SE, Joyce AE, Zhao Y, Ledbetter DJ. Why is erythropoietin present in human milk? Studies of erythropoietin receptors on enterocytes of human and rat neonates. Pediatr Res.\u20081999;46(3):263\u2013268","DOI":"10.1203\/00006450-199909000-00003"},{"key":"2021120906001048200_R44","doi-asserted-by":"crossref","unstructured":"Juul SE, Ledbetter DJ, Joyce AE, et al. Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut.\u20082001;49(2):182\u2013189","DOI":"10.1136\/gut.49.2.182"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/122\/2\/383\/1034754\/zpe00808000383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/122\/2\/383\/1034754\/zpe00808000383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:02:41Z","timestamp":1639094561000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/122\/2\/383\/73084\/A-Phase-I-II-Trial-of-High-Dose-Erythropoietin-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2008,8,1]]},"published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-2711","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}